ESC 365 - Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis

Open Access

Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis

Session: Congestion, SGLT2 inhibitors and novel therapies

Topic: Pharmacotherapy

Speaker: Associate Professor D. D'Amario (Novara, IT)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Associate Professor Domenico D'Amario

University of Eastern Piedmont, Novara (Italy)

4 presentations

1 follower

5 more presentations in this session

Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalaemia a barrier?

Speaker: Professor E. Kelepouris (Philadelphia, US)

Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.

Speaker: Doctor A. Michel (Basel, CH)

Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease

Speaker: Assistant Professor A. Sahin (Sivas, TR)

Introduction and optimization of the guideline-directed medical therapy in patients hospitalized for acute heart failure (OPTICARD)

Speaker: Doctor G. Baudry (Nancy, FR)

The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure

Speaker: Doctor I. Lala (Arad, RO)

Access the full session

Congestion, SGLT2 inhibitors and novel therapies

Speakers: Associate Professor D. D'Amario, Professor E. Kelepouris, Doctor A. Michel, Assistant Professor A. Sahin, Doctor G. Baudry...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources